BUSINESS

• Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
  February 23, 2016

• Shionogi’s Naldemedine Yields Positive PIII Results for Opioid-Induced Constipation
  February 23, 2016

• Fuso’s Voluntary Recall Escalated to Order-Based Recall
  February 23, 2016

• Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
  February 22, 2016

• Merck Serono Likely to Halt Serophene Sales in Japan, Notification Sent Out to Medical Societies
  February 22, 2016

• Sanofi Suffers 6.6% Decline in Japan Revenues
  February 22, 2016

• Fuso Voluntarily Recalls Maltose-Lactated Ringer’s Inj. and Replas Injection Due to Mislabeling
  February 22, 2016

• Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
  February 19, 2016

• Fujifilm Begins US PI Study for Cancer Drug FF-10502
  February 19, 2016

• Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
  February 19, 2016

• US Merck to Sell Daiichi Sankyo’s Lixiana in 13 European Countries
  February 18, 2016

• JCR to Roll Out Cell Therapy Temcell on Feb. 24; Medipal to Be Exclusive Distributor
  February 18, 2016

• Genzyme Japan to Be Merged into Sanofi in July
  February 17, 2016

• Eisai, Sysmex Link Up in Next-Gen Diagnostic Reagents for Dementia
  February 16, 2016

• Shionogi Joins Cambridge Therapeutic Consortium
  February 16, 2016

• Asahi Kasei, Pfizer Wind Up Recomodulin Copromotion Scheme
  February 16, 2016

• Otsuka’s Pharma Sales Down Nearly 15% in 2015
  February 15, 2016

• Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
  February 15, 2016

• Astellas Completes Acquisition of Ocata
  February 15, 2016

• Alecensa Japan PIII Trial Halted Early for Benefit
  February 12, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 481
• 482
• 483
• 484
• 485
• 486
• 487
• 488
• 489
• …
• Next ›
• 最終 »